MX2024004214A - Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados. - Google Patents
Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.Info
- Publication number
- MX2024004214A MX2024004214A MX2024004214A MX2024004214A MX2024004214A MX 2024004214 A MX2024004214 A MX 2024004214A MX 2024004214 A MX2024004214 A MX 2024004214A MX 2024004214 A MX2024004214 A MX 2024004214A MX 2024004214 A MX2024004214 A MX 2024004214A
- Authority
- MX
- Mexico
- Prior art keywords
- kras
- irinotecan
- inhibitors
- combinations
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252405P | 2021-10-05 | 2021-10-05 | |
| PCT/US2022/045625 WO2023059600A1 (en) | 2021-10-05 | 2022-10-04 | Combinations of kras g12d inhibitors with irinotecan and related methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004214A true MX2024004214A (es) | 2024-07-29 |
Family
ID=85803676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004214A MX2024004214A (es) | 2021-10-05 | 2022-10-04 | Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250249003A1 (https=) |
| EP (1) | EP4412720A4 (https=) |
| JP (1) | JP2024537137A (https=) |
| KR (1) | KR20240073115A (https=) |
| CN (1) | CN118354794A (https=) |
| AU (1) | AU2022361219A1 (https=) |
| CA (1) | CA3233571A1 (https=) |
| IL (1) | IL311863A (https=) |
| MX (1) | MX2024004214A (https=) |
| WO (1) | WO2023059600A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
-
2022
- 2022-10-04 AU AU2022361219A patent/AU2022361219A1/en active Pending
- 2022-10-04 CN CN202280077625.0A patent/CN118354794A/zh active Pending
- 2022-10-04 JP JP2024520703A patent/JP2024537137A/ja active Pending
- 2022-10-04 KR KR1020247015024A patent/KR20240073115A/ko active Pending
- 2022-10-04 CA CA3233571A patent/CA3233571A1/en active Pending
- 2022-10-04 EP EP22879177.8A patent/EP4412720A4/en active Pending
- 2022-10-04 MX MX2024004214A patent/MX2024004214A/es unknown
- 2022-10-04 IL IL311863A patent/IL311863A/en unknown
- 2022-10-04 US US18/695,032 patent/US20250249003A1/en active Pending
- 2022-10-04 WO PCT/US2022/045625 patent/WO2023059600A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL311863A (en) | 2024-06-01 |
| KR20240073115A (ko) | 2024-05-24 |
| CA3233571A1 (en) | 2023-04-13 |
| JP2024537137A (ja) | 2024-10-10 |
| EP4412720A1 (en) | 2024-08-14 |
| WO2023059600A1 (en) | 2023-04-13 |
| EP4412720A4 (en) | 2025-08-13 |
| CN118354794A (zh) | 2024-07-16 |
| US20250249003A1 (en) | 2025-08-07 |
| AU2022361219A1 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004215A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1. | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| MX2024004214A (es) | Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados. | |
| MX2024009727A (es) | Terapias de combinacion. | |
| MX2023015236A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer. | |
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| ZA202300875B (en) | Kat6 inhibitor methods and combinations for cancer treatment | |
| PH12021552675A1 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
| EA202190749A1 (ru) | Способы комбинированной терапии | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| CR20240144A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| MX2020011684A (es) | Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer. | |
| MX2025008920A (es) | Inhibidores de parp1 triciclicos y usos de estos | |
| AU2010266004A8 (en) | Method of treating cancer with Dll4 antagonist and chemotherapeutic agent | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| PH12022553501A1 (en) | Alk2 inhibitors for the treatment of anemia | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 | |
| MX2025001990A (es) | Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. |